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Abstract
Objective
This study was conducted to evaluate the preventive effect of lamotringine on 
migraine aura and migraine attacks in children, afflicted with classic migraine. 
Material & Methods
Conducted between October 2005 and April 2008 in the neurology clinic of 
Kashani hospital, Shahrekord, this study was a clinical trial, aimed at evaluating 
the prophylactic effects of Lamotringine administered to 21 children suffering 
from migraine with aura.
Results
Of the subjects, 52.4% of patients were female. The most common type of aura 
was visual (42.9%). Following use of Lamotrigine, significant reductions were 
seen in the frequency (from 5 ± 0.83 to 3.04  ± 1.65) and in intensity (from 6. 33 
± 1.08 to 3.66  ± 1.1) of migraine aura (P= 0.002). After 6 months of drug usage 
66.6% of patients were improved. 
Conclusion
Lamotringine is effective in reducing the migraine aura and intensity of attacks 
in patients suffering from migraine with aura, and is hence beneficial for 
prophylactic therapy in children with classic migraine.
Key words: Lamotringine, Migraine aura, Classic migraine, children, 
prophylaxis
Introduction   
Migraine is one of the most chronic common neurological disorders, afﬂicting 
more females (13-18%) than males (4.6 %) (1). 
The prevalence of migraine has been reported to be 4% in children aged 7-14 years, 
in Sweden (2), 2.7 % at age seven and 10.6 % at fourteen, in Finland (3). Migraine 
is with or without aura with the ratio of one to ﬁve (1-4). In comparison to adults, 
the attacks in children are generally shorter in duration and frequency. One study 
reported the duration of migraine headaches in 61% of children to be less than 
ﬁve hours, with only 17% of children experiencing headaches early morning (3). 
Nausea and vomiting, other than headaches, are the main features of migraine in 
children, which have been reported in 81% of 7 year old patients (4).
Of the various theories regarding the pathogenesis of migraine or migraine aura, 
one of the most important is cortical spreading depression (CSD), a phenomenon 
usually associated with elevation of central nervous system hydrogen and potassium 
Mirzaei M.G.R. MD 1, 
Azimian  M. MD 2, 
Moezzi M. MD 3, 
Vameghi R. MD 4;
Rafieian-kopaei M. MD 5,
EFFECT OF LAMOTRIGINE ON PROPHYLAXIS OF PEDIATRIC 
CLASSIC MIGRAINE
Received : 20-01-2009,
Last revised: 04-05-09,
Accepted: 23-06-09
36 Iran J Child Neurology  June  2009
ion, with the release of glutamate and nitrous oxide as 
excitatory neurotransmitters (2). The term CSD is used 
to describe a depression of spontaneous EEG and other 
cortical activities spreading across the cerebral cortex 
due to activity of noxious stimuli (5). The glutamate 
system is also described as a possible mechanism leading 
to neuronal hyperexcitability and CSD (6). Glutamate is 
increased in both forms of migraine, more markedly in 
migraine with aura (7). Also recent experiments have 
demonstrated that CSD depends on activation of a 
subtype glutamate receptor (8, 9).
Abnormal release of glutamate usually triggers an 
aura and migraine attacks, and the agents that inhibit 
glutamate release may be useful for prophylactic 
therapy in migraine with aura (9, 10). Lamotrigine, as 
an antiepileptic drug, inhibits sodium (Na) channels and 
also reduces glutamate release (10-13). In this regard, 
lamotrigine, as an inhibitory neurotransmitter (14, 15) 
has been shown to be effective in adult migraine attacks 
(14, 16, 17). This clinical study aimed to evaluate the 
preventive effect of lamotrigine on children between the 
ages of 4 - 14 years, with migraine headache. Duration 
of headaches, type of aura, common clinical symptoms, 
and the effects of sex and age on migraine headaches 
were also evaluated in this study. 
Materials & Methods 
This clinical trial, conducted between October 2005 and 
April 2008, in neurology clinic of Kashani hospital in 
Shahrekord, Iran, investigated a group of 21 pediatric 
patients, suffering from migraine with aura. Patients 
aged between 4 – 14 years of age were eligible if they 
were currently suffering from classic migraine with 
at least 2 attacks per month. Diagnosis was based on 
the International Headache Society (IHS) criteria and 
neurological examinations. Electroencephalography 
(EEG) and brain computed tomography scan (CT) 
were also obtained, when necessary (15). Patients 
with previous consumption of lamotringine (during 3 
months before trial), hepatic and cardiac problems, or 
hypersensitivity were excluded from the study. Twenty-
one patients with classic migraine eligible for this study 
were enrolled.
Type of aura, frequency and intensity of headaches were 
recorded for a period of 2 months prior to initiation 
of drug usage, and patients were followed up for 6 
months. 
Primary dose of lamotringine was 0.5 mg/kg/day and 
patients were evaluated monthly; intensity of headache 
was recorded for each migraine attack for 2 months 
before drug usage and 6 months following lamotrigine 
administration, on a scale of 0 to 10, with 0 = none, 1-3= 
mild, 4-7 = moderate, and 8-10 = severe. In this study 
improvement was considered as 50% reduction in the 
frequency of attacks and reduction of intensity to none 
or mild. Lamotrigine doses for patients not responding to 
initial drug doses were increased gradually (up to 3mg/
kg/day) until their frequency and intensity of attacks 
decreased to the above mentioned levels; these doses 
were then continued until the end of the experiments. 
Data were analyzed by SPSS 16 using non parametric 
tests (Wilcoxon rank test, Chi square and Mann-Whitney 
U test). P< 0.05 was considered as signiﬁcant.
Results 
The patients mean age was 8.9 ± 1.94 (range 4 to 12 y); 
52.4% were female.  Results of the Wilcoxon rank test 
showed signiﬁcant difference between both frequency 
(P= 0.002) and intensity (P=0.002) of migraine before 
and after treatment (table 1).
Table 1: Lamotrigine effects on migraine attacks 
(n=21).
            Quantity
  Migraine attacks 
Mean+SD Range P.value
Frequency 
 After 5+0.83 (4-6)
0.002
Before 3.04+1.6 (1-6)
Intensity  
Before 6.33+1.08 (2-10)
0.002
After 3.66+1.1 (0- 9)
Drug doses were from 0.5 to 3 mg/kg/day, the most 
effective doses being between 1.5 and 2 mg/kg/day. 
Following lamotringine usage, the percentage of patients 
with severe, moderate, mild and no intensity, changed 
from 23.8 to 14.3%, 66.7 to 28.6%, 38.1% to 9.5 % and 
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19% to zero respectively. Man Whitney U and Chi square 
tests showed that there was no signiﬁcant difference for 
sex or age between groups that showed improvement 
and those that did not.
Of the improved patients, 66.5% had reduction or 
complete improvement in just their aura. In 42.8% of 
patients, lamotringine was effective on both aura and 
headaches.
Discussion  
In adult females, the prevalence of migraine headache 
is 5 fold that of adult males (1); however in children 
migraine occur equally in both genders,(3), ﬁndings 
similar to the results of our study. 
The dose of lamotringine, most effective in the 
prophylaxis of migraine headache, ranged between 0.5 
and 2 mg/kg/day. Unfortunately we were unable to ﬁnd 
any similar studies on children to compare ours with. 
Studies on adult migraine with aura have used doses 
ranging between 75 to 150 mg/day for prophylaxis (4, 
16).
This study showed that lamotringine was effective in 
reducing the frequency and intensity of migraine with 
aura. In this regard signiﬁcant reduction was seen in the 
intensity of attacks following lamotrigine administration. 
Improvement of aura and headache was seen in 42.8% 
of cases and improvement of aura in 66.5%. 
Studies on adult migraine with aura have also 
demonstrated a signiﬁcant reduction in frequency 
and intensity of migraine with aura (4, 16, 17). The 
effectiveness of lamotrigine on the frequency of adult 
migraine with aura has been reported to be between 50 
(4, 10, 13, 15) to 80% (17). 
Lamotringine probably, suppresses glutamate release, 
which could be the main reason for the prophylactic 
effect of this drug on migraine with aura. Glutamate, as 
the key neurotransmitter is involved in the development 
and propagation of the neurophysiological correlate of 
the aura (8). Plasma and cerebrospinal glutamate levels 
have been shown to be higher in migraine with aura in 
comparison to migraine without aura (13). Therefore, 
if high glutamate levels should be responsible for 
cortical spreading depression and the clinical symptoms 
of migraine aura, lamotrigine might suppress this 
phenomenon and thus prevent aura development. The 
effective suppression of aura symptoms of lamotrigine 
may be due to the potent presynaptic and postsynaptic 
inhibition of glutamate, indicating that lamotrigine may 
act as an NMDA (N-methyl-D-aspartic acid) antagonist 
(18, 19).
In conclusion, lamotringine is effective in reducing 
migraine aura and intensity of attacks in migraine with 
aura and is an appropriate drug for the prophylactic 
therapy in children with classic migraine.
The results of this study showed that in children, 
migraine frequency was higher, duration was shorter 
and that visual and gastrointestinal problems were the 
most auras among them, results that are conﬁrmed by 
other studies (3, 5).
Of the study limitations that deserve comment, ﬁrst, 
there was no placebo control group to be compared. 
Of course, having a placebo group for 6 months or 
more was not ethical. Second, we did not measure 
the serum concentration of the drug. Perhaps, the 
serum concentration of lamotringine, compared to the 
administered dose would be a better guide to evaluate 
the clinical response, and we suggest this be considered 
in future studies 
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